TLC and Jixi Biotechnology Partners have signed an agreement to form a joint venture in TLC Biopharmaceuticals with the purpose to conduct clinical studies, register, and commercialize TLC’s pipeline for the China market.   The China Food and Drug Administration recently rolled out initiatives designed to accelerate drug approvals and encourage innovation, including greater alignment of China’s review process with that of the US and the EU. This partnership aims to act in line with those...